← board
QNCX
Quince Therapeutics S.p.A.distress 6/10 · elevated risk$18.17-2%today-98% from 52w high
Lead: Ataxia-Telangiectasia
Revenue
pre-revenue
Liquidity
$18M
Runway
0.5 yrs
Shares 1y
-70%
Price & events
-97.2% over 6M
CatalystRating changeDilutionFinancingdashed = today
-2.0%
1D
-2.7%
1W
-6.1%
1M
-33.2%
3M
-97.1%
6M
-95.1%
1Y
-88.0%
2Y
-99.9%
5Y
-99.7%
All
Overview
- Market Cap
- $296.18M
- Enterprise Value
- $278.02M
- Volume
- 2.24K
- 52 Week Range
- $16.00 – $880
- Total Shares
- 16.30M
- Float Shares
- 731.87K
- Short %
- 11.57%
- % Held by Insiders
- 0.32%
- % Held by Institutions
- 14.21%
- RVOL
- 0.07x
- Beta
- 1.40
Pipeline stages · 1 programs
Dexamethasone sodium phosphate
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Pipeline · 2 trials · 0 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| 2026-01-30 | Phase 3 | Dexamethasone sodium phosphate | Ataxia Telangiectasia | 101 | terminated |
| 2025-12-17 | Phase 3 | Dexamethasone sodium phosphate | Ataxia Telangiectasia | 105 | completed |
Catalyst news & presentations · 8
- second half of 2026Guided 55%regulatory submissionFiled (NDA/BLA)eDSP · plans to submit NDA to FDA assuming positive resultsSEC 8-K
- 2026-08-11Estimated 45%earningsEarningsEarnings releaseyahoo
- 2026-05-17partnershipAcquisition of Orphai Therapeutics via mergerSEC 8-K
- 2026-04-27fda agreementRegained compliance with Nasdaq minimum bid price requirement (Listing Rule 5450(a)(1)).SEC 8-K
- first quarter of 2026readoutPhase 3eDSP · expects to report topline results from Phase 3 NEAT clinical trialSEC 8-K
- 2026-01-29trial discontinuedeDSP · Company to cease clinical development of eDSP.SEC 8-K
- 2025-10-17withdrawalN-acetyl-L-leucine · Quince retracted its statement that IntraBio's Phase 2 study for NALL in ataxia-telangiectasia failed across all endpoints; statement was based on an incorrect source (a single-site study, not the Phase 2 study).SEC 8-K
- completed enrollmentenrollment completesecondaryPhase 3eDSP · completed enrollment in pivotal Phase 3 NEAT clinical trial with 105 participantsSEC 8-K
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
buy · target $83 (+359% upside) · 3 analysts
- 2026-06-24Leerink PartnersOutperform
- 2026-06-23Cantor FitzgeraldOverweight
- 2026-01-30CitizensMarket Outperform → Market Perform
- 2026-01-30D. Boral CapitalBuy → Hold
- 2026-01-29D. Boral CapitalBuy
- 2025-12-15D. Boral CapitalBuy
Competitors — Ataxia-Telangiectasia
- none identified
Recent news
- 2026-07-18QUINCE THERAPEUTICS INC (QNCX) Stock Chart - ChartMill
- 2026-07-15QNCX Q1 2026 Earnings: Stunning EPS Surprise of 210.29% as Company Reports $57.6 Per Share - dars.gov.et
- 2026-07-13QNCX Q1 2026 Earnings: EPS Surges to $57.6, Crushing Estimates Amid Strong Stock Reaction - Earnings Revision Report - dars.gov.et
- 2026-07-09Quince Therapeutics Inc (QNCX) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
- 2026-07-08QNCX Q1 2026 Earnings: Massive EPS Surprise Driven by One-Time Gain, Pipeline Progress in Focus - Adjusted Earnings Analysis - DonanımHaber
- 2026-07-08Intelligent Driving Computing System Market - Global Forecast 2026-2032 - GlobeNewswire
- 2026-07-07Quince Therapeutics updates its strategy as a clinical-stage biotech. QNCX focuses on targeted drug - Ad-hoc-news.de
- 2026-07-03QNCX Should I Buy - Intellectia AI
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.